INmune Bio, Inc. (NASDAQ:INMB) Q4 2025 Earnings Call Transcript March 30, 2026 INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.26. Operator: Greetings, and ...
In a pivotal year for INmune Bio, the company has made significant strides in advancing its therapeutic platforms, yielding ...
The average one-year price target for INmune Bio (NasdaqCM:INMB) has been revised to $7.14 / share. This is an increase of 33.33% from the prior estimate of $5.36 dated February 21, 2026. The price ...
But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn ...
Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March 19, 2026 ...
4d
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
INmune Bio Inc (INMB) reports significant progress in clinical trials and regulatory plans, despite increased net loss and asset impairment.
INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its financial results for the year ended December 31, 2025 ...
The last time I spoke about INmune Bio (INMB) it was with a Seeking Alpha article entitled "INmune Bio: Alzheimer's Disease Treatment Lottery Ticket". With this article, I noted its prospects about ...
OmniScience and INmune Bio (INMB) announced a partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease, or AD, clinical trial using OmniScience’s product, Vivo, a ...
(Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its ...
Dr. Tesi and Mr. Moss will be available for one-on-one meetings throughout the conference. Please contact your Oppenheimer salesperson to schedule one-on-one meetings with the management team. About ...
Q4 2025 Earnings Call March 30, 2026 4:30 PM EDTCompany ParticipantsDaniel Carlson - Head of Investor RelationsDavid Moss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results